Amy is a UK and European patent attorney in our Life Sciences and Chemistry group and joined Kilburn & Strode in February 2021, having previously worked for four years at another private practice firm. She has extensive expertise in the biotechnology sector, with a particular focus on complex biologics, including bispecific antibodies, non-standard antibody formats, T-cell based therapeutics and CAR-T technology. She has a strong track record in technically complex patent prosecution and significant experience handling contentious matters before the European Patent Office (EPO). She assists a range of clients, from academic instructions and early stage startups through to Fortune 500 companies, and is passionate about helping clients maximise the value of their IP.
Amy holds a BSc and PhD in Neuroscience from University College London. Her doctoral research focused on gene expression and its role in seizure risk and synaptic dysfunction in Alzheimer’s Disease and Down Syndrome. She has completed research projects in the UK and Germany and has hands-on experience across multiple disciplines, including molecular biology, genetics, pharmacology, cellular neuroscience, electrophysiology, and behavioural neuroscience.
Amy is passionate about the intersection of technology and life sciences, and has a particular interest in the legal and practical implications of machine learning in the biotech space.